

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5429993

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
HENRIK TELLER	01/29/2019
ALEXANDROS VAKALOPOULOS	01/24/2019
MELISSA BOULTADAKIS ARAPINIS	01/24/2019
ALEXANDER STRAUB	01/31/2019
HANNA TINEL	01/24/2019
MARKUS BRECHMANN	01/21/2019
MATTHIAS BEAT WITWER	02/03/2019
MAXIMILIAN ANDREAS KULLMANN	01/24/2019
TILL FREUDENBERGER	01/31/2019
THOMAS MONDRITZKI	01/24/2019
TOBIAS MARQUARDT	01/24/2019

RECEIVING PARTY DATA

Name:	BAYER AKTIENGESELLSCHAFT
Street Address:	KAISER-WILHELM-ALLEE 1
City:	LEVERKUSEN
State/Country:	GERMANY
Postal Code:	51373
Name:	BAYER PHARMA AKTIENGESELLSCHAFT
Street Address:	MÜLLERSTR. 178
City:	BERLIN
State/Country:	GERMANY
Postal Code:	13353

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16333079

CORRESPONDENCE DATA

Fax Number: (650)494-0792

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

PATENT

Phone: (650) 813-5662
Email: ebowers@mofo.com
Correspondent Name: JANE KUZELKA
Address Line 1: MORRISON & FOERSTER LLP
Address Line 2: 755 PAGE MILL ROAD
Address Line 4: PALO ALTO, CALIFORNIA 94304-1018

ATTORNEY DOCKET NUMBER: 77705-20304.00

NAME OF SUBMITTER: JANE KUZELKA

SIGNATURE: /Jane Kuzelka/

DATE SIGNED: 03/19/2019

Total Attachments: 10

source=77705-20304.00 Assignment#page1.tif
source=77705-20304.00 Assignment#page2.tif
source=77705-20304.00 Assignment#page3.tif
source=77705-20304.00 Assignment#page4.tif
source=77705-20304.00 Assignment#page5.tif
source=77705-20304.00 Assignment#page6.tif
source=77705-20304.00 Assignment#page7.tif
source=77705-20304.00 Assignment#page8.tif
source=77705-20304.00 Assignment#page9.tif
source=77705-20304.00 Assignment#page10.tif

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

ASSIGNMENT

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, 1) BAYER AKTIENGESELLSCHAFT

2) BAYER PHARMA AKTIENGESELLSCHAFT of 1) Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, DE

2) Müllerstr. 178, 13353 Berlin, DE, (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts known to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:

- The attached application, OR United States Application or PCT International Application
Number PCT/EP2017/072339 filed on 2017-09-06 (Confirmation No. _____).

PRE-AIA

My residence, mailing address, and citizenship are as stated below next to my name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

1. Dr. Henrik TELLER
18258 Schwaan, DE *18209 Hohensfelde, DE*
Alte Weide 40a, *Am Schwarzen Beck 10, 18209*
18258 Schwaan, DE *Hohensfelde, DE*
DE
Henrik Teller 29.01.2019

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

2. Dr. Alexandros VAKALOPOULOS
40721 Hilden, DE
Heinrich-Heine-Str. 79a, 40721 Hilden, DE
GR

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

3. Dr. Melissa BOULTADAKIS ARAPINIS
40215 Düsseldorf, DE
Fürstenwall 135, 40215 Düsseldorf, DE
FR

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

4. Dr. Alexander STRAUB
42113 Wuppertal, DE
Kaufbachstr. 20, 42113 Wuppertal, DE
DE

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

5. Dr. Hanna TINEL
42113 Wuppertal, DE
In der Bäck 16, 42113 Wuppertal, DE
PL

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

6. Dr. Markus BRECHMANN
San Francisco, CA 94114, US
3833 18th Street, San Francisco, CA 94114, US
DE

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

7. Dr. Matthias Beat WITWER
4125 Riehen, CH
Rüchligweg 49, 4125 Riehen, CH
CH

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

8. Dr. Maximilian Andreas KULLMANN
42799 Leichlingen, DE
Am Treppchen 5, 42799 Leichlingen, DE
DE

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

9. Dr. Tili FREUDENBERGER
42553 Velbert, DE
Zum Jahnsportplatz 44, 42553 Velbert, DE
DE

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

ASSIGNMENT

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, 1) BAYER AKTIENGESELLSCHAFT

2) BAYER PHARMA AKTIENGESELLSCHAFT of 1) Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, DE

2) Müllerstr. 178, 13353 Berlin, DE, (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts known to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:

- The attached application, OR United States Application or PCT International Application
Number PCT/EP2017/072339 filed on 2017-09-06 (Confirmation No. _____).

PRE-AIA

My residence, mailing address, and citizenship are as stated below next to my name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.

FULL NAME OF INVENTOR: 1. Dr. Henrik TELLER
RESIDENCE: 18258 Schwaan, DE
POST OFFICE ADDRESS: Alte Weide 40a, 18258 Schwaan, DE
CITIZENSHIP: DE
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 2. Dr. Alexandros VAKALOPOULOS
RESIDENCE: 40721 Hilden, DE
POST OFFICE ADDRESS: Heinrich-Heine-Str. 79a, 40721 Hilden, DE
CITIZENSHIP: GR
SIGNATURE / DATE A. VAKALOPOULOS 24/01/19

FULL NAME OF INVENTOR: 3. Dr. Melissa BOULTADAKIS ARAPINIS
RESIDENCE: 40215 Düsseldorf, DE
POST OFFICE ADDRESS: Fürstenwall 135, 40215 Düsseldorf, DE
CITIZENSHIP: FR
SIGNATURE / DATE M. Boulதாகის 24/01/19

FULL NAME OF INVENTOR: 4. Dr. Alexander STRAUB
RESIDENCE: 42113 Wuppertal, DE
POST OFFICE ADDRESS: Kaulbachstr. 20, 42113 Wuppertal, DE
CITIZENSHIP: DE
SIGNATURE / DATE Alexander Straub 31.1.19

FULL NAME OF INVENTOR: 5. Dr. Hanna TINEL
RESIDENCE: 42113 Wuppertal, DE
POST OFFICE ADDRESS: In der Beek 16, 42113 Wuppertal, DE
CITIZENSHIP: PL
SIGNATURE / DATE Hanna Tinel 24.01.19

FULL NAME OF INVENTOR: 6. Dr. Markus BRECHMANN
RESIDENCE: San Francisco, CA 94114, US
POST OFFICE ADDRESS: 3833 18th Street, San Francisco, CA 94114, US
CITIZENSHIP: DE
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 7. Dr. Matthias Beat WITTWER
RESIDENCE: 4125 Riehen, CH
POST OFFICE ADDRESS: Rütchligweg 49, 4125 Riehen, CH
CITIZENSHIP: CH
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 8. Dr. Maximilian Andreas KULLMANN
RESIDENCE: 42799 Leichlingen, DE
POST OFFICE ADDRESS: Am Treppchen 5, 42799 Leichlingen, DE
CITIZENSHIP: DE
SIGNATURE / DATE M. Kullmann 24.01.19

FULL NAME OF INVENTOR: 9. Dr. Till FREUDENBERGER
RESIDENCE: 42553 Velbert, DE
POST OFFICE ADDRESS: Zum Jahnsportplatz 44, 42553 Velbert, DE
CITIZENSHIP: DE
SIGNATURE / DATE Till Freudenberg 31.01.2019

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

ASSIGNMENT

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, 1) BAYER AKTIENGESELLSCHAFT

2) BAYER PHARMA AKTIENGESELLSCHAFT of 1) Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, DE

2) Müllerstr. 178, 13353 Berlin, DE, (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts known to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:

- The attached application, OR United States Application or PCT International Application
Number PCT/EP2017/072339 filed on 2017-09-06 (Confirmation No. _____).

PRE-AIA

My residence, mailing address, and citizenship are as stated below next to my name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.


FULL NAME OF INVENTOR: 1. Dr. Henrik TELLER
RESIDENCE: 18258 Schwaan, DE
POST OFFICE ADDRESS: Alte Weide 40a, 18258 Schwaan, DE
CITIZENSHIP: DE
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 2. Dr. Alexandros VAKALOPOULOS
RESIDENCE: 40721 Hilden, DE
POST OFFICE ADDRESS: Heinrich-Heine-Str. 79a, 40721 Hilden, DE
CITIZENSHIP: GR
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 3. Dr. Melissa BOULTADAKIS ARAPINIS
RESIDENCE: 40215 Düsseldorf, DE
POST OFFICE ADDRESS: Firstenwall 135, 40215 Düsseldorf, DE
CITIZENSHIP: FR
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 4. Dr. Alexander STRAUB
RESIDENCE: 42113 Wuppertal, DE
POST OFFICE ADDRESS: Kaufbachstr. 20, 42113 Wuppertal, DE
CITIZENSHIP: DE
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 5. Dr. Hanna TINEL
RESIDENCE: 42113 Wuppertal, DE
POST OFFICE ADDRESS: In der Beek 16, 42113 Wuppertal, DE
CITIZENSHIP: PL
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 6. Dr. Markus BRECHMANN
RESIDENCE: San Francisco, CA 94114, US
POST OFFICE ADDRESS: 3833 18th Street, San Francisco, CA 94114, US
CITIZENSHIP: DE
SIGNATURE / DATE  01/21/2019

FULL NAME OF INVENTOR: 7. Dr. Matthias Beat WITWERT
RESIDENCE: 4125 Riehen, CH
POST OFFICE ADDRESS: Rühligweg 49, 4125 Riehen, CH
CITIZENSHIP: CH
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 8. Dr. Maximilian Andreas KULLMANN
RESIDENCE: 42799 Leichlingen, DE
POST OFFICE ADDRESS: Am Treppchen 5, 42799 Leichlingen, DE
CITIZENSHIP: DE
SIGNATURE / DATE _____

FULL NAME OF INVENTOR: 9. Dr. THH FREUDENBERGER
RESIDENCE: 42553 Velbert, DE
POST OFFICE ADDRESS: Zum Jahnsportplatz 44, 42553 Velbert, DE
CITIZENSHIP: DE
SIGNATURE / DATE _____

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

ASSIGNMENT

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, 1) BAYER AKTIENGESELLSCHAFT

2) BAYER PHARMA AKTIENGESELLSCHAFT of 1) Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, DE

2) Müllerstr. 178, 13353 Berlin, DE, (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts known to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:

- The attached application, OR United States Application or PCT International Application
Number PCT/EP2017/072339 filed on 2017-09-06 (Confirmation No. _____).

PRE-AIA

My residence, mailing address, and citizenship are as stated below next to my name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(v), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.

FULL NAME OF INVENTOR: 1. Dr. Henrik TELLER
RESIDENCE: 18258 Schwaan, DE
POST OFFICE ADDRESS: Alte Weide 40a, 18258 Schwaan, DE
CITIZENSHIP: DE
SIGNATURE / DATE

FULL NAME OF INVENTOR: 2. Dr. Alexandros VAKALOPOULOS
RESIDENCE: 40721 Hilden, DE
POST OFFICE ADDRESS: Heinrich-Heine-Str. 79a, 40721 Hilden, DE
CITIZENSHIP: GR
SIGNATURE / DATE

FULL NAME OF INVENTOR: 3. Dr. Melissa BOULTADAKIS ARAPINIS
RESIDENCE: 40215 Düsseldorf, DE
POST OFFICE ADDRESS: Fürstenwall 135, 40215 Düsseldorf, DE
CITIZENSHIP: FR
SIGNATURE / DATE

FULL NAME OF INVENTOR: 4. Dr. Alexander STRAUB
RESIDENCE: 42113 Wuppertal, DE
POST OFFICE ADDRESS: Kaufbachstr. 20, 42113 Wuppertal, DE
CITIZENSHIP: DE
SIGNATURE / DATE

FULL NAME OF INVENTOR: 5. Dr. Hanna TINEL
RESIDENCE: 42113 Wuppertal, DE
POST OFFICE ADDRESS: In der Beek 16, 42113 Wuppertal, DE
CITIZENSHIP: PL
SIGNATURE / DATE

FULL NAME OF INVENTOR: 6. Dr. Markus BRECHMANN
RESIDENCE: San Francisco, CA 94114, US
POST OFFICE ADDRESS: 3833 18th Street, San Francisco, CA 94114, US
CITIZENSHIP: DE
SIGNATURE / DATE

FULL NAME OF INVENTOR: 7. Dr. Matthias Beat WITWER
RESIDENCE: 4125 Riehen, CH
POST OFFICE ADDRESS: Rüdligweg 49, 4125 Riehen, CH
CITIZENSHIP: CH
SIGNATURE / DATE *Matthias Witwer* 3-FEB-2019

FULL NAME OF INVENTOR: 8. Dr. Maximilian Andreas KULLMANN
RESIDENCE: 42799 Leichlingen, DE
POST OFFICE ADDRESS: Am Treppchen 5, 42799 Leichlingen, DE
CITIZENSHIP: DE
SIGNATURE / DATE

FULL NAME OF INVENTOR: 9. Dr. Till FREUDENBERGER
RESIDENCE: 42553 Velbert, DE
POST OFFICE ADDRESS: Zum Jakusportplatz 44, 42553 Velbert, DE
CITIZENSHIP: DE
SIGNATURE / DATE

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)**ASSIGNMENT**

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, 1) BAYER AKTIENGESELLSCHAFT

2) BAYER PHARMA AKTIENGESELLSCHAFT of 1) Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, DE

2) Müllerstr. 178, 13353 Berlin, DE, (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts known to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:

- The attached application, OR United States Application or PCT International Application
Number PCT/EP2017/072339 filed on 2017-09-06 (Confirmation No. _____).

PRE-AIA

My residence, mailing address, and citizenship are as stated below next to my name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

10. Dr. Thomas MONDRITZKI
45130 Essen, DE
Julienstrasse 59, 45130 Essen, DE
DE

 _____ 24.1.2019

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

11. Dr. Tobias MARQUARDT
42115 Wuppertal, DE
Viktoriastr. 81, 42115 Wuppertal, DE
DE

 _____ 24.1.2019